RWC-340B says Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently applies also to hospitals’ non-340B-purchased “own use” drugs.
Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.
The Q2 2022 registration period for 340B overlaps with the April 14 deadline for hospitals that lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork for reinstatement.
The next period for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, April 1, and end on Friday, April 15.
Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies
Charity care at five Massachusetts hospital groups declined at a time that 340B sales to the hospitals were rising, a new report by a conservative state think tank says. The state hospital association says the report distorts the 340B program.
Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.
HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
HRSA yesterday told Congress in its budget request that it needed comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program.
Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although
Mid Delta Health Center is a member of Community Health Centers of Arkansas, which wants to intervene in PhRMA's lawsuit challenging the state's one-of-a-kind law protecting 340B contract pharmacy arrangements.
Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
Trent Smith is the new Managing Director of Ryan White Clinics for 340B Access.
Ryan White Clinics for 340B Access (RWC-340B) and its management services consultant have chosen Trent Smith, a former manager and director in both the nonprofit and for-profit sectors, to be RWC-340B’s new managing director.
The federal government has decided to intervene in a 340B-related whistleblower lawsuit involving Methodist University Hospital in Memphis, Tenn.
The federal government has decided to intervene in a whistleblower lawsuit that accuses a Tennessee health system of paying Memphis-area cancer physicians for referrals that allegedly generated about $70 million a year in profits for the health system